Pregabalin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PHARMAC (New Zealand) and SMC (Scotland), among others, recommended or restricted pregabalin, while PBAC (Australia) did not recommend it.
Where pregabalin met resistance it was usually narrowed rather than refused: 3 of 7 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The file has been open for more than a decade: 17.5 years separate the first record, 10 Jan 2005 at SMC (Scotland), from the most recent, 2022 at PBAC (Australia).
TLV (Sweden) changed its position: recommended on 3 Feb 2005, restricted by 13 Jul 2015.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for pregabalin by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 12 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess pregabalin, on 10 Jan 2005; PBAC (Australia) did not open a file until 2021 — an unusually long tail of 16.5 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 3 of 7 decisive outcomes narrowed pregabalin to a subgroup rather than accepting or refusing it outright, at SMC (Scotland) and TLV (Sweden).
4 of the 6 agencies here assessed pregabalin more than once, TLV (Sweden) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for pregabalin.
The full ledger for pregabalin reads 3 restricted, 3 recommended, 2 other and 1 not recommended, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2022 | Neuropathic pain | Not recommended | source |
| PHARMAC (New Zealand) | 7 Dec 2017 | Generalised anxiety disorder | funding application decided · decision reached | source |
| HAS (France) | 3 May 2017 | Listing renewal (Transparency Committee) | SMR substantial | source |
| TLV (Sweden) | 13 Jul 2015 | Lyrica oral lösning ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| AWMSG (Wales) | 25 Nov 2011 | Treatment of peripheral and central neuropathic pain in adults and as adjunctive therapy in adults with partial seizures… | outside AWMSG criteria | source |
7 further decisions for pregabalin, across 5 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- paracetamol — same ATC class N02B — Analgesics
- paracetamol / tramadol — same ATC class N02B — Analgesics
- ziconotide — same ATC class N02B — Analgesics
- methoxyflurane — same ATC class N02B — Analgesics
- adefovir dipivoxil — also decided by PHARMAC in 2017Q4
- adalimumab — also decided by PHARMAC in 2017Q4
Coverage: 12 decisions for pregabalin from 6 agencies, 2005 to 2022. Data to 7 Sep 2026. ATC class N02B — Analgesics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.